Genelux Announces Exclusive License Agreement with ELIAS Animal Health for V-VET1, a Proprietary Oncolytic Vaccination Virus Treatment for Pets with Various Cancers

– V-VET1, a clinical animal health specific product candidate, is a vaccinia virus strain that selectively replicates in cancer cells causing cell death (apoptosis)

– The terms of the agreement grant ELIAS the worldwide right to develop and market V-VET1 for the diagnosis, prevention and treatment of cancer in veterinary medicine

VILLAGE OF WESTLAKE, California., November 18, 2021 / PRNewswire / – Genelux Company, a clinical-stage immunotherapy company, today announced an exclusive global licensing agreement for V-VET1, its clinical-stage animal health product candidate, with ELIAS Animal Health, a biotechnology company advancing its new immunotherapies based on T cells for the treatment of cancer in veterinary medicine. V-VET1 is a vaccinia virus strain that selectively replicates in cancer cells causing cell death (apoptosis).

Genelux logo

ELIAS Animal Health is planning future clinical trials to evaluate and develop V-VET1 as a potential new immunotherapy option for veterinary oncologists. Under the terms of the agreement, Genelux will receive upfront payment, development and sales milestones, as well as royalties on product sales.

Genelux conducted a Phase 1 study in which V-VET1 was administered to dogs with several types of cancer, including mast cells, osteosarcoma, soft tissue sarcoma, anal gland carcinoma and cell lymphoma. T. No maximum tolerated dose was reached in this dose escalation trial and the dogs tolerated their infusions well. Evidence of anti-tumor and disease control responses has been observed.

Cancer is the leading cause of death in dogs and the number one pet health problem for dog owners in United States. In addition to surgery, currently available canine cancer treatment generally offers limited survival benefit. The Comparative Oncology Program of the National Cancer Institute Cancer Research Center has reported that up to six million companion dogs and six million companion cats are diagnosed with cancer each year in United States.

“We are delighted to be working with ELIAS Animal Health to advance V-VET1 for the treatment of dogs and other non-human animals with various cancers,” said Thomas zindrick, JD, President and CEO of Genelux. “Unfortunately, there are currently few exclusively veterinary drugs to treat pets with cancer. ELIAS does a tremendous job advancing new animal health treatments, including advanced adoptive T cell therapy combined with surgery and radiation therapy, and we are proud to partner with them. “

“We are delighted to announce our exclusive license for V-VET1 to help veterinarians treat the many pets that are diagnosed with cancer each year,” said Tammie Wahaus, CEO of ELIAS Animal Health. “This therapy has shown promising data in the Phase 1 study, and we look forward to expanding our portfolio to expand the cancer treatment options available in veterinary medicine.”

About ELIAS Animal Health
Situated at Olathe, Kan., ELIAS Animal Health is a medical biotechnology company developing its new targeted immunotherapies based on T cells for the treatment of canine cancers. ELIAS cancer immunotherapy is commercially distributed to veterinarians under 9 CFR 103.3 as an autologous prescription investigational product for the treatment of canine osteosarcoma. The company’s new therapeutic approach offers the promise of improved clinical outcomes and the potential to fundamentally change the way cancer is treated. For more information visit www.eliasanimalhealth.com.

About Genelux Corporation
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients with aggressive and / or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary and modified strain of vaccinia virus (VACV), a stable DNA virus with high engineering capability. The core of Genelux’s discovery and development efforts revolve around the company’s proprietary CHOICE ™ platform from which the company has developed an extensive library of immunotherapeutic product candidates isolated and designed for vaccinia virus. oncolytic, including Olvi-Vec. For more information, please visit www.genelux.com.

Contacts
Genelux Company
[email protected]

Tiberend Strategic Advisors, Inc.
Lisa Sher (Investors)
[email protected]

David Schemelia (Media)
[email protected]

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/genelux-announces-exclusive-out-licensing-agreement-with-elias-animal-health-for-v-vet1-a-proprietary-oncolytic-vaccinia-virus- treatment-for-animals-with-various-cancers-301427526.html

SOURCE Genelux Corporation


Source link

Boyd S. Abbott